4 Result: FibroGen
Pharvaris Gains Momentum, Avalo Therapeutics and FibroGen Suffer Setbacks
June 26th, 2023
Shares of Pharvaris N.V. (Nasdaq: PHVS) surged over 10% in pre-market trading after the clinical-stage company announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug (IND) application f. Read more
FibroGen Trial Disappoints, UnitedHealth Dividend Boost, Oracle and Ultragenyx Ratings Update
June 07th, 2023
FibroGen, Inc. (Nasdaq: FGEN) announced the topline data from the Phase 3 LELANTOS-1 trial, evaluating pamrevlumab as a treatment for non-ambulatory patients with Duchenne Muscular Dystrophy (DMD) on background corticosteroids. Unfortunately. Read more
Chijet Motor Debuts on Nasdaq, Market Experts Bullish on Ambrx, FibroGen, Bowlero, REGENXBIO and Kopin
June 02nd, 2023
Chijet Motor Company, Inc. (Nasdaq: CJET) achieved a significant milestone as it officially joined the ranks of NASDAQ-listed companies under the ticker symbol "CJET" on Friday. With a core focus on the development, manufacturing, sales, and. Read more
Monro Falls Short of Q4 Expectations as Micron Technology, Mullen Automotive, and FibroGen Make Positive Pre-Market Moves
May 18th, 2023
Monro, Inc. (Nasdaq: MNRO) has released its financial results for the fourth quarter of fiscal 2023, reporting adjusted earnings per share (EPS) that fell short of market expectations. The company's adjusted EPS for the quarter stood at $0.08, compar. Read more
Want To Find Some News?
News By Industries
Recent Post
-
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025Earnings Preview: Credo Technology, MongoDB, and Hafnia in Focus
November 30th, 2025
Member Login